FDA TEMPO Pilot Lets Generative-AI Medical Devices Launch Without Marketing Authorization

The FDA has launched TEMPO, a pilot that lets developers ship generative-AI medical devices without prior marketing authorization while regulators gain real-world experience with the technology. Four devices from Cadence, Limbic and two others have been accepted; the program is tied to the Medicare ACCESS model for chronic-condition management.